251 related articles for article (PubMed ID: 37197006)
1. Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
Kim Y; Yamamoto S; Kato K
Cancer Manag Res; 2023; 15():399-406. PubMed ID: 37197006
[TBL] [Abstract][Full Text] [Related]
2. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
4. Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer.
Hirose T; Yamamoto S; Kato K
Therap Adv Gastroenterol; 2023; 16():17562848221148250. PubMed ID: 36644131
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Ikeda G; Miyakoshi J; Yamamoto S; Kato K
Future Oncol; 2024 Apr; 20(11):665-677. PubMed ID: 38126175
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Wang R; Liu S; Chen B; Xi M
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291954
[TBL] [Abstract][Full Text] [Related]
9. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
[TBL] [Abstract][Full Text] [Related]
10. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial).
Yin J; Lin S; Fang Y; Jiao H; Chen Z; Tang H; Gu J; Zhang S; Sun L; Li Y; Han Y; Chen Q; Chen H; Li Z; Tan L
J Thorac Dis; 2023 Feb; 15(2):718-730. PubMed ID: 36910109
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
[TBL] [Abstract][Full Text] [Related]
14. Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
Zheng Y; Li C; Yu B; Zhao S; Li J; Chen X; Li H
JTCVS Open; 2022 Mar; 9():293-299. PubMed ID: 36003437
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M;
N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008
[TBL] [Abstract][Full Text] [Related]
16. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
19. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y
World J Gastroenterol; 2023 Sep; 29(34):5020-5037. PubMed ID: 37753366
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
Shen D; Chen Q; Wu J; Li J; Tao K; Jiang Y
J Gastrointest Oncol; 2021 Feb; 12(1):1-10. PubMed ID: 33708420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
